14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CCAP vs BCSF: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Crescent Capital BDC, Inc. (CCAP) captures the overall head-to-head institutional edge over Bain Capital Specialty Finance, Inc. (BCSF) on higher Unified Composite conviction (19.6/100 STRONG SELL vs. 39.6/100 SELL) after splitting the core matrix 4–6 (led by Valuation Multiples), while BCSF wins 4–1 across the 6-pillar growth and valuation breakdown. CCAP trades at $10.08 (7.0x Forward P/E, 78.4% operating margin) versus BCSF at $10.87 (8.1x Forward P/E, 76.8% operating margin).
Composite vs. Pillar Nuance: While BCSF currently prints a higher short-term Unified Composite Score (39.6/100 SELL vs. CCAP 19.6/100 STRONG SELL), CCAP captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (78.4% vs. 76.8% operating margin) and revenue trajectory (-15.5% vs. -10.9% YoY).
Defensive Composite Rating Caution: Although CCAP compares more favorably head-to-head, both CCAP (19.6/100 STRONG SELL) and BCSF (39.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: CCAP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 61.3); meanwhile BCSF is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CCAP vs BCSF. Trailing 12-month operating profitability (CCAP 78.4% vs BCSF 76.8%) and valuation multiples (CCAP 7.0x vs BCSF 8.1x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Asset Management value chain with $372.1M market capitalization and 78.4% operating margin.
OpEx & R&D Reinvestment21.6% of Rev ($34M)
90D Engineering Disclosures0 Published
BCSF Moat ProfileHigh-Margin Pricing Power Moat
Asset Management Operator
Competes within the Asset Management value chain with $717.4M market capitalization and 76.8% operating margin.
OpEx & R&D Reinvestment23.2% of Rev ($60M)
90D Engineering Disclosures0 Published
Investor FAQ CCAP vs BCSF Key Questions & Quantitative Answers
As of Nov 16, 2026, Crescent Capital BDC, Inc. (CCAP) captures the overall head-to-head institutional edge over Bain Capital Specialty Finance, Inc. (BCSF) on higher Unified Composite conviction (19.6/100 STRONG SELL vs. 39.6/100 SELL) after splitting the core matrix 4–6 (led by Valuation Multiples), while BCSF wins 4–1 across the 6-pillar growth and valuation breakdown. CCAP trades at $10.08 (7.0x Forward P/E, 78.4% operating margin) versus BCSF at $10.87 (8.1x Forward P/E, 76.8% operating margin). Composite vs. Pillar Nuance: While BCSF currently prints a higher short-term Unified Composite Score (39.6/100 SELL vs. CCAP 19.6/100 STRONG SELL), CCAP captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (78.4% vs. 76.8% operating margin) and revenue trajectory (-15.5% vs. -10.9% YoY). Defensive Composite Rating Caution: Although CCAP compares more favorably head-to-head, both CCAP (19.6/100 STRONG SELL) and BCSF (39.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: CCAP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 61.3); meanwhile BCSF is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BCSF leads the Growth & Scale pillar: CCAP posts -15.5% YoY revenue growth and -14.9% YoY earnings growth on $156M TTM revenue (100.0% gross margin, 78.4% operating margin), compared with BCSF at -10.9% YoY revenue growth and -10.7% YoY earnings growth on $257M TTM revenue (100.0% gross margin, 76.8% operating margin). On trailing 12-month operating scale, CCAP generates $156M in USD-normalized revenue versus $257M for BCSF. In operating R&D and SG&A reinvestment, CCAP deploys 21.6% of Rev ($34M) (0 90-day corporate R&D disclosures) versus 23.2% of Rev ($60M) (0 disclosures) for BCSF.
CCAP screens cheaper on headline valuation multiples. CCAP trades at 7.0x Forward P/E, 7.4x Trailing P/E, 0.89x PEG, and 2.4x EV/Revenue (unreported cash flow margin), whereas BCSF trades at 8.1x Forward P/E, 11.5x Trailing P/E, 1.05x PEG, and 2.8x EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CCAP (-0.5% ROE) versus BCSF (5.6% ROE) capital efficiency.
In options market volatility and institutional positioning, CCAP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 50% Vol realized risk). By comparison, BCSF carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 27% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.